Kornimate/medical-research-clean huggingface dataset:
sas in patients with bronchial carcinoma

Conditions: Sleep Apnea Syndrome; Bronchial Carcinoma

Summary: in this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of apnealink device by resmed.

determination of the sas- frequence in patients with bronchial carcinoma. the patients will be screened at home for 1 night with the apnealink device by resmed. the apnealink device is a standard screening tool for sleep apnea in clinical practice.

Eligibility criteria:
inclusion criteria: * patients with reasonable suspicion of bronchial carcinoma or histologically proven bronchial carcinoma, which has not been medicated until the study entry and * patients with sleep apnea who had recently been diagnosed with bronchial carcinoma. exclusion criteria: * pregnancy * other already known malignancies or tumors * patients with non-invasive artificial respiration due to a chronic respiratory insufficiencies

Keywords: apnealink bronchial carcinoma sleep apnea screening
tolerability of rebif® injection with and without the use of rebiject™mini in relapsing-remitting multiple sclerosis subjects

Conditions: Multiple Sclerosis, Relapsing-remitting

Summary: this is a randomized, multicenter, parallel-group, open-label study comparing the tolerability of rebif® injections (44 microgram \[mcg\] administered subcutaneously three times a week) with and without rebiject™mini, an auto-injection device in relapsing-remitting multiple sclerosis (ms) subjects. subjects will be randomly assigned to either one of the two rebif® groups in a 1:1 ratio on study day 1 stratified by center. subjects will receive a minimum of 3 months of treatment with rebif® 44 mcg three times a week and will be asked to assess their injection site reactions on a weekly basis. clinic visit will occur at 1 and 3 months after the initiation of treatment.


Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years of age * has relapsing-remitting ms * are willing and able to comply with the protocol for the duration of the study exclusion criteria: * has significant leukopenia/lymphopenia (white blood cell count less than (\<) 0.5 times the lower limit of normal) * has elevated liver function tests (aspartate aminotransferase \[ast\], alanine transaminase \[alt\], or alkaline phosphatase greater than (\>) 2 times the upper limit of normal or total bilirubin \> 1.5 times the upper limit of normal) * has an allergy to human serum albumin or mannitol * had treatment with an investigational product or procedure within 3 months * has the presence of systemic disease or abnormal laboratory findings that might interfere with subject safety, compliance or evaluation of the condition under study * has concomitant use of avonex®, betaseron®, copaxone®, or novantrone®

Keywords: ms
a study to evaluate safety, tolerability, and pharmacokinetics of sol-804 in healthy male subjects

Conditions: Prostate Cancer

Summary: study design : a randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study

to evaluate the safety, tolerability and pharmacokinetic characteristics of sol-804-f and zytiga tablets following a single oral dose and zytiga 1,000 mg in healthy male volunteers.

Eligibility criteria:
inclusion criteria: 1. healthy adult male volunteers between 19 to 50 years of age at screening visit. 2. body mass index (bmi) between 19.0 to 30.0 kg/m2 3. the subjects voluntarily decide to participate in the study after receiving a full explanation and understanding and provide written consent 4. the subjects are suitable for this study as determined by the investigator (physical examination, clinical laboratory tests, etc.) exclusion criteria: 1. clinically significant abnormal physical examination, vital signs or ecg 2. the subjects who have a medical history of hepatobiliary, renal, neurological, immune, respiratory, endocrine, hematologic, oncologic, cardiovascular, urinary, psychiatric or sexual dysfunction. 3. the subjects who have a hereditary disorder including galactose intolerance, lapp lactase deficiency, glucose-galactose malabsorption, etc. 4. the subjects who have a history of drug abuse or positive with urine drug screening test

Keywords: abiraterone
the effectiveness of hemopatch® in the reduction of post-surgical serous drainage

Conditions: Hemopatch; Breast Cancer; Axillary Lymphadenectomy

Summary: hemopatch is an alternative to reduce morbidity associated with axillary lymphadenectomy surgery, possibly contributing to improved patient management, clinical outcomes, and hospital costs. we propose a multicenter, controlled, and randomized trial to study the efficacy of hemopatch in reducing serous wound drainage.


Eligibility criteria:
inclusion criteria preoperative: * female gender * age ≥ 18 years * breast cancer n+ * conservative surgery: lumpectomy or quadrantectomy * berg levels 1-2 axillary lymphadenectomy intraoperative: * axillary incision separated from the incision for the breast lesion * placement of a closed low pressure suction drain in the axillary fossa * hemostasis and lymphostasis using clips, electrocautery, electric scalpel or bipolar coagulation postoperative: - patients with ≥ 10 axillary nodes removed exclusion criteria preoperative: * mastectomy * previous radiation therapy * previous axillary emptying * liver pathology * diabetic decompensation: defined as any episode that has required medical attention in an emergency service or hospital admission; and also that which has required a modification of the patient's drugs, or an increase of more than 20% of the total daily dose. * known allergies to any component of hemopatch (proteins of bovine origin or peg) * psychiatric disorder that conditions the non-understanding of the questionnaire, or incapacitation of the patient to understand it * simultaneous participation in another clinical study * pcr positive for sars-cov-2 intraoperative: * level 3 axillary dissection (severe axillary involvement) * unexpected surgical contraindication * hemostasis and lymphostasis: ultrasonic techniques or other advanced energy techniques are excluded. * use of fibrin sealants (eg: tisseel, artiss, tachosil), cyanoacrylate type adhesives (eg: glubran-2) or other types of products (oxidized cellulose format, powders or gelatin sheets or collagen).
impact of oral magnesium on neuropathic pain

Conditions: Patient With Neuropathic Pain

Summary: use lay language. the aim of this study is to evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. the study drug will be taken during 4 weeks.

protocol description visit d0 * patient inclusion after informed signed consent * clinical exam * blood sampling (magnesium dosage) * questionnaires (neuropathic pain and quality of life) * daily self-evaluation on neuropathic pain scale (week0 to week5) d8 : first intake of study drug (magnesium or placebo) visit week5: * questionnaires (neuropathic pain and quality of life) * blood sampling (magnesium dosage) * clinical exam

Eligibility criteria:
inclusion criteria: - neuropathic pain - informed signed consent exclusion criteria: * magnesium intake contra-indication * severe renal insufficiency * quinidine intake * concomitant treatment change 2weeks before inclusion * evolutive pathology

Keywords: neuropathic pain, magnesium
effects of coffee roasting on blood sugar levels in healthy humans

Conditions: Hyperglycemia

Summary: the present study determined the effects light, medium, and dark roasted, brewed coffees on blood glucose responses in normal (n = 19) subjects.

this is a single-blinded, randomized partial block design conducted over 6 weeks in two parts. in part 1 (3 weeks), participants were randomly assigned to consume four beverages: a placebo containing water and caramel color, light, medium, or dark roast coffee before, during, or after consumption of a beverage containing 50 g of glucose. in part 2 (3 weeks), participants were randomly assigned to consume four beverages: a placebo containing water and caramel color, light, medium, or dark roast coffee before, during, or after consumption of a standardized breakfast (corn flakes cereal + skim milk) containing 50 g of glucose. in each part, fasting and postprandial glucose profiles were determined.

Eligibility criteria:
inclusion criteria: • age 18-64 years old with bmi less than 29 and fasting blood glucose less than 125 mg/dl. exclusion criteria: * age 18-64 years old with bmi less than 29 and fasting blood glucose less than 125 mg/dl. * weight less than 110 pounds (55 kg) * pre-existing health conditions, such as: * high cholesterol * hypertension * cardiovascular disease * gastrointestinal motility disorders * hypo- or hyperthyroidism * anemia * renal disease * liver disease, including hepatitis b or c, cholestasis, cirrhotic liver disease, or non-alcoholic fatty liver disease * chronic or acute pancreatitis * diabetes type 1 or 2 * insulin resistance * polycystic ovary syndrome * food allergies or intolerances to coffee/caffeine/dairy/corn-based cereals. * currently taking prescription medication * current smoker * consumes more than 3 alcoholic beverages per day * pregnant or breastfeeding * not willing to take their own blood samples with finger sticks

Keywords: coffee glucose challenge blood glucose levels
the roles of exosomal circ-lrba and 451/crtc2 signaling axis in colorectal cancer

Conditions: Colorectal Cancer

Summary: colorectal cancer (crc) is one of the most common malignant tumors in the world. most of the patients with colorectal cancer were diagnosed in poor stage. although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. in recent years, molecular targeted therapy has shown significant efficacy in specific patients. it was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. the changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. at present, metastasis and recurrence still be the most difficult problems in treatment. therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. these will be important clinical significance for targeted therapy of colorectal cancer.


Eligibility criteria:
inclusion criteria: 1.18-80 years old. 2.18.5 \< bmi \< 27.9. 3. the surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer. exclusion criteria: 1. those who refuse to collect samples. 2. patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases. 3. patients who has a history of neoadjuvant radiotherapy or chemotherapy. 4. combining with distant multiple metastases of tumor
hrv and pain intensity

Conditions: Chronic Pain

Summary: the aim of this study is to explore the association between pain intensity and heart rate variability in patients with chronic pain.


Eligibility criteria:
inclusion criteria: * patients with chronic pain for at least 3 months * age \> 18 years * patient has been informed of the study procedures and has given written informed consent * patient willing to comply with study protocol exclusion criteria: * healthy patients or patients with acute pain. * evidence of an active disruptive psychiatric disorder that may impact perception of pain, and/or ability to evaluate treatment outcome as determined by investigator * patients were excluded if they had one or more coexisting conditions known to affect hrv analysis.
pet/mr for prostate cancer restaging: a phase ii prospective monocentric study

Conditions: Prostate Cancer

Summary: the overall goal is to provide an innovative approach to restage patients with biochemical recurrence of prostate cancer by using hybrid pet/mr with innovative radiotracers (68ga-psma and 68ga-rm2)

sixty consecutive patients with biochemical recurrence (psa≥0.2 ng/ml), previously treated with radical prostatectomy for organ confined prostate cancer will be enrolled; patients with previous and/or concomitant androgen deprivation therapy will be excluded from enrolment. all patients will undergo both 68ga-psma pet/mr and 68ga-rm2 pet/mr imaging at san raffaele scientific institute in two different days; all clinical and pathological variables available at the time of pet/mr studies will be recorded for each patient. pet/mr results will be compared to other imaging procedures performed and available in the course of routinely work-up evaluation. treatment approach will be based on all available clinical and instrumental data, including 68ga-psma and 68ga-rm2 pet/mr, evaluated during multidisciplinary sessions including expert urologists, nuclear medicine and radiologist physicians. patients with local recurrence will be candidate to salvage radiation therapy (srt). patients presenting only ln recurrence will be proposed to be submitted to salvage lymph node (ln) dissection (slnd) or srt; alternatively, conventional androgen deprivation therapy will be performed in those patients who will not be willing to undergo secondary surgery or radiation therapy. to assess the diagnostic accuracy of 68ga-psma and 68ga-rm2 pet/mr, images will be validated with: 1) histology (when deemed necessary by the clinician as expected under the normal care pathway) obtained by echographically-guided biopsy in suspected local recurrence or during slnd in the event of suspected nodal recurrence; 2) biochemical response after tailored treatment in patients submitted to srt for local or ln recurrence 3) conventional imaging modalities performed to assess disease status as part of the routine clinical work-up. 68ga-psma and 68ga-rm2 pet/mr will be correlated with available clinical and pathological features. to assess the impact of 68ga-psma pet/mr and 68ga-rm2 pet/mr in changing patients' management, patients will be followed-up after the execution of pet/mr studies. patients will be followed-up until the end of the study period

Eligibility criteria:
inclusion criteria: * patients with histological proven diagnosis of prostate cancer. * patients treated with radical therapy (rp o ebrt, with or without further adjuvant therapies), who present rising serum psa values ≥ 0.2 ng/ml. * age ≥ 18 years-old. * willing to provide a signed informed consent. exclusion criteria: * age \< 18 years-old. * previous and/or concomitant androgen deprivation therapy will be excluded. * any additional medical condition that may significantly interfere with study compliance. * contraindications to mr study (i.e. pacemaker

Keywords: prostate cancer biochemical recurrence pet/mr
subtalar extra-articular screw arthroereisis

Conditions: Flatfoot, Flexible

Summary: the aim of the study is to investigate the effect of subtalar extra-articular calcaneo-stop screw on the proprioceptive and nociceptive pathways of the ankle before and after implantation. the hypothesis of the study is that an increased number of receptors related to proprioception will be detected in the sinus tarsi.


Eligibility criteria:
inclusion criteria: study group: * patients aged 14 years old and above that will remove the calcaneo stop screw, in place for at least 3 years after the implant, will be recruited * patients willing and able to give informed consent for the participation in the study. for underage patients, a parent/legal representative will give consent for the participation in the study. * male and female patients in fertile age can be recruited. control group: * syndromic patients * previous foot malformation (synostosis, congenital clubfoot) * female participant who is pregnant, lactating or planning pregnancy during the course of the study. exclusion criteria: control group: * syndromic patients * previous foot malformation (synostosis, congenital clubfoot) * female participant who is pregnant, lactating or planning pregnancy during the course of the study. study group: * patients suffering from post-operative complications * syndromic patients * previous foot malformation (synostosis, congenital clubfoot) * female participant who is pregnant, lactating or planning pregnancy during the course of the study.
test uniformity of transdermal drug delivery to breast using diclofenac epolamine

Conditions: Breast Cancer

Summary: the purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. the drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. the drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.

this is a randomized study where participants in group 1 will apply the diclofenac epolamine patch to the breast and participants in group 2 will apply the same drug to her abdomen. participants are instructed to apply a new patch every 12 hours for 3 days. total participation in this study will be for three days, ending on the day of surgery. on the day of surgery, participants will have blood drawn to measure the level of diclofenac epolamine in the body, and the final patch will be removed.

Eligibility criteria:
inclusion criteria: * women between the ages of 18 and 80 years, undergoing total mastectomy for, with or without axillary surgery for diagnosis or prevention of breast cancer. * ecog performance status less than 2. * ability to understand and the willingness to sign a written informed consent. * participants must have normal organ and marrow function exclusion criteria: * prior history of ipsilateral breast radiotherapy. * pregnant women and those who will be actively breast-feeding in the preoperative period will be excluded. * inability to discontinue aspirin or warfarin use during the period of participation. * known allergy to diclofenac epolamine, or aspirin, diclofenac (cataflam, voltaren), or another non-steroidal anti-inflammatory drug (nsaid). * renal failure

Keywords: women undergoing total mastectomy breast cancer prevention
the nash-wo-numa (childhood growth & development) study

Conditions: Adolescent Development; Stunting; Depression; Micronutrient Deficiency

Summary: the proposed study will be a cross-sectional study in the district of matiari, pakistan. children ages 9-15 years will be identified from a matiari district household census scheduled being conducted from december 2016- to may 2017 by the department of pediatrics and child health, aga khan university. anthropometric measures, tanner stage, hemoglobin concentration, blood draw as well as questionnaires will be assessed in all participants.


Eligibility criteria:
inclusion criteria: * all girls between 9.0-14.9 years of age and boys between 10.0-15.9 years of age at the time of enrollment who are permanent residents of matiari are eligible to participate in the nash-wo-numa study. * the participant's birth mother must also be available to participate in the study and be cognitively able to answer questions since they will be able to provide more accurate information about the birth characteristics of the participant as well as household information like dietary intake exclusion criteria: * children not meeting the age criteria will not be invited to participate in the study. female participants who are pregnant or have been pregnant will be excluded from the study. * participants must not be participating in any other nutrition trials. participants with known chronic or genetic diseases that impact growth will be excluded. * an illustrative list of conditions include: congenital heart disease, metabolic disorders (e.g. diabetes), cancer, genetic disorders (down's syndrome, turner's syndrome), blood disorders (symptomatic thalassemia, sickle cell anaemia), chronic disorders (kidney i.e. nephrotic syndrome, gastrointestinal i.e. crohn's, bone dysplasia, immunodeficiency disorders).
the use of electrical stimulation to increase anal pressures

Conditions: Fecal Incontinence

Summary: the goal of this clinical trial is to learn about the feasibility of inducing contraction of the anal sphincter by transcutaneous neuromuscular electrical stimulation in patients with fecal incontinence. the main questions it aims to answer are: * efficacy of the specific stimulation protocol to increase anal pressures * tolerability and safety participants will be exposed to the stimulation with the changes in pressure will be studied using high resolution anorectal manometry


Eligibility criteria:
inclusion criteria: * undergoing anorectal manometry for the evaluation of fecal incontinence indication * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * \>18 years old exclusion criteria: * pregnant or attempting to become pregnant. the safety of electronic muscle stimulators during pregnancy has not been established. * an electronic implant (e.g. cardiac pacemaker, implanted defibrillator) or suffer from heart problems. * conductive intra-uterine devices (iud/coil) or metal implants in the abdominal or pelvic area, including the hip and lumbar spine * cancer, epilepsy, or cognitive dysfunction. * pelvic floor surgery within the last six weeks. * complete denervation of the pelvic floor. * advanced full thickness rectal prolapse. * injured, inflamed or any significant disease in the peri-anal skin. * allergy to any component of the device, either known of developed during testing. * moderate to severe proctitis of any etiology. * skin irritation at the site of the stimulating electrodes
a study of abatacept in patients with active crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active crohn's disease in patients who have not had an adequate response to other therapies. the safety of this treatment will also be studied.


Eligibility criteria:
inclusion criteria: * 18 years or older * have had crohn's disease for at least 3 months * moderate to severely active crohn's disease * have had an inadequate response or intolerance to other crohn's disease treatments